EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Combining immune‐checkpoint inhibitors with tocilizumab to treat a lung adenocarcinoma patient with pre‐existing polymyalgia rheumatica: A case report

Yang Du, Xiao-Yan Liu, Li Zhang iD

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15176 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Yang Du und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medic…. Hauptthemen laut MEDLINE: Polymyalgia Rheumatica, Adenocarcinoma of Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune‐checkpoint inhibitors (ICIs) have changed the management of advanced cancers. However, patients with pre‐existing autoimmune diseases (ADs) have usually been excluded from clinical trials of ICIs due to concerns about exacerbation of AD. Here, we combined ICIs with selective immunosuppressant treatment in a metastatic lung adenocarcinoma patient with active pre‐existing polymyalgia rheumatica (PMR). Remarkably, the strategy led to durable response and no exacerbation of PMR. Thus, we provide the first clinical evidence of treating metastatic cancer with ICIs and concomitant use of tocilizumab and hydroxychloroquine for active pre‐existing PMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polymyalgia RheumaticaAdenocarcinoma of LungLung NeoplasmsAntibodies, Monoclonal, HumanizedHumansImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

immune checkpoint inhibitorlung cancerpolymyalgia rheumaticatocilizumab

Substanzen

tocilizumabImmune Checkpoint InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

ORCID-Profile: Li Zhang

Zitieren

APA

Du, Y., Liu, X. Y., & Zhang, L. (2024). Combining immune‐checkpoint inhibitors with tocilizumab to treat a lung adenocarcinoma patient with pre‐existing polymyalgia rheumatica: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15176

Vancouver

Du Y, Liu XY, Zhang L. Combining immune‐checkpoint inhibitors with tocilizumab to treat a lung adenocarcinoma patient with pre‐existing polymyalgia rheumatica: A case report. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15176

BibTeX
@article{Du2024,
  author = {Du, Yang and Liu, Xiao-Yan and Zhang, Li},
  title = {Combining immune‐checkpoint inhibitors with tocilizumab to treat a lung adenocarcinoma patient with pre‐existing polymyalgia rheumatica: A case report},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15176}
}
Kostenlos starten →